Efavirenz

Generic Name
Efavirenz
Brand Names
Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva
Drug Type
Small Molecule
Chemical Formula
C14H9ClF3NO2
CAS Number
154598-52-4
Unique Ingredient Identifier
JE6H2O27P8
Background

Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.
...

Indication

For use in combination treatment of HIV infection (AIDS)

Associated Conditions
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Associated Therapies
-
Clinical Trials
Related News

Evaluation of Two Anti-HIV Treatment Strategies in Resource-Limited South African Communities

First Posted Date
2005-11-21
Last Posted Date
2011-06-21
Lead Sponsor
CIPRA SA
Target Recruit Count
812
Registration Number
NCT00255840

When to Start Anti-HIV Drugs in Children Infected With HIV (The PREDICT Study)

First Posted Date
2005-10-06
Last Posted Date
2013-12-04
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
300
Registration Number
NCT00234091
Locations
🇰🇭

National Pediatric Hosp., Cambodia CIPRA CRS, Phnom Penh, Cambodia

🇰🇭

Social Health Clinic, Cambodia CIPRA CRS, Phnom Penh, Cambodia

🇹🇭

Prapokklao Hosp. CIPRA CRS, Chantaburi, Thailand

and more 6 locations

Combination of Efavirenz and Truvada - COMET Study

Phase 4
Completed
Conditions
HIV Infections
First Posted Date
2005-09-23
Last Posted Date
2008-04-10
Lead Sponsor
Gilead Sciences
Target Recruit Count
400
Registration Number
NCT00224458

An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection

Conditions
HIV Infection
First Posted Date
2005-09-13
Last Posted Date
2014-01-09
Lead Sponsor
Bristol-Myers Squibb
Registration Number
NCT00162227
Locations
🇺🇸

Children'S Hospital, Boston, Massachusetts, United States

🇺🇸

State University Of New York At Stony Brook, Stony Brook, New York, United States

🇺🇸

Metro Health Medical Center, Cleveland, Ohio, United States

and more 21 locations

An Expanded Access Study of Oral Liquid Efavirenz in the Treatment of Children With HIV Infection: Canada

Conditions
HIV Infection
First Posted Date
2005-09-13
Last Posted Date
2014-01-09
Lead Sponsor
Bristol-Myers Squibb
Registration Number
NCT00162188
Locations
🇨🇦

Local Institution, Montreal, Quebec, Canada

Feasibility Study of a Once Daily Antiretroviral Regimen in Vietnam (ANRS 1210 VIETAR)

Phase 3
Completed
Conditions
HIV Infection
First Posted Date
2005-09-12
Last Posted Date
2007-07-03
Lead Sponsor
French National Agency for Research on AIDS and Viral Hepatitis
Target Recruit Count
100
Registration Number
NCT00158470
Locations
🇻🇳

Binh Trieu Hospital, Ho Chi Minh City, Vietnam

🇻🇳

Tropical Diseases Hospital, Ho Chi Minh City, Vietnam

Study Switching HIV-1 Infected Patients With an Undetectable Viral Load on a First Protease Inhibitor-Based Regimen to an Efavirenz-Based Regimen

Phase 3
Completed
Conditions
HIV Infections
First Posted Date
2005-08-26
Last Posted Date
2010-02-17
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
254
Registration Number
NCT00135382
Locations
🇵🇷

Local Institution, Rio Piedras, Puerto Rico

2NN & CHARM Long-Term Follow-up Study

Phase 4
Completed
Conditions
HIV Infections
First Posted Date
2005-08-09
Last Posted Date
2007-04-30
Lead Sponsor
International Antiviral Therapy Evaluation Center
Target Recruit Count
763
Registration Number
NCT00127972
Locations
🇦🇺

Holdsworth House Medical Practice, Darlinghurst, Australia

Virological and Clinical Anti-Hepatitis B Virus (HBV) Efficacy of Tenofovir and Emtricitabine in Patients With HIV/HBV co-Infection

Phase 4
Completed
Conditions
HIV Infections
Hepatitis B
First Posted Date
2005-08-09
Last Posted Date
2007-04-24
Lead Sponsor
International Antiviral Therapy Evaluation Center
Target Recruit Count
24
Registration Number
NCT00127959
Locations
🇳🇱

Academic Medical Center, Amsterdam, NH, Netherlands

Early Versus Standard Start of Anti-HIV Therapy for Treatment-Naive Adults in Haiti

Not Applicable
Completed
Conditions
HIV Infections
Tuberculosis
Interventions
Drug: Efavirenz
Drug: Lamivudine/Zidovudine
First Posted Date
2005-07-18
Last Posted Date
2014-10-15
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
816
Registration Number
NCT00120510
Locations
🇭🇹

Les Centres GHESKIO CIPRA CRS, Port au Prince, Haiti

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy